activity
20112025
most citedAn information-theoretic Phase I/II design for molecularly targeted agents that does not require an assumption of monotonicity

37 citations · 75 across the 30 of their papers we have counts for

collaborators
Showing 2025Show all

2 papers · 1 filter

stat.ME2025

Using joint models in phase I dose-finding designs in oncology: considerations for frequentist approaches

Xijin Chen, Pavel Mozgunov, Richard D. Baird +1

Dose-finding trials for oncology studies are traditionally designed to assess safety in the early stages of drug development. With the rise of molecularly targeted therapies and im…

stat.ME2025

A multi-arm multi-stage design for trials with all pairwise testing

Peter Greenstreet, Thomas Jaki, Alun Bedding +1

Multi-arm multi-stage (MAMS) trials have gained popularity to enhance the efficiency of clinical trials, potentially reducing both duration and costs. This paper focuses on designi…